Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 4, 2009, Pages 255-261

  Rocha, J F ^a   Vaz da Silva, M ^a   Almeida, L ^a   Falcao A ^b   Nunes, T ^a   Santos, A T ^a   Martins, F ^c   Fontes Ribeiro, C ^c   Macedo, T ^c   Soares da Silva, P ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b Health Limited   (Portugal)

^c ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

Author keywords

Drug interaction; ESL; Eslicarbazepine; Eslicarbazepine acetate; Healthy subjects; Metformin; Pharmacokinetics

Indexed keywords

ESLICARBAZEPINE ACETATE; METFORMIN; RISIDON; UNCLASSIFIED DRUG;

ACUTE GASTROENTERITIS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 65549151370     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47255     Document Type: Article

References (17)

1. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-Silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol. 2005; 45: 1062-1066.
2. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008; 64: 267-273.
3. Almeida L, Soares-da-Silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol. 2004; 44: 906-918.
4. Bonifacio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia. 2001; 42: 600-608.
5. Chow S-C, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokin Pharmacodyn. 2001; 28: 155-169.
6. Elger C, BialerM, Cramer JA, Maia J, Almeida L, Soaresda- Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007; 48: 497-504.
7. EMEA/CPMP. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/1401/98, The European Agency for the Evaluation of Medicinal Products (EMEA), London; 2001.
8. Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soaresda-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos. 2007; 28: 249-256.
9. FDA/CDER. Center for Drug Evaluation and Research (CDER). Bioavailability and bioequivalence studies for orally administered drug products - general considerations. U.S. Department of Health and Human Services, Food and Drug Administration; 2000.
10. Fontes-Ribeiro C, Nunes T, Falcão A, Neta C, Lima R, Tavares S, Almeida L, Macedo T, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093): Relative bio availability and bioequivalence of 50 mg/ml oral suspension and 200 mg and 800 mg tablet formulations. Drugs R&D. 2005; 6: 253-260.
11. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, Potgieter MA, Soares-da-Silva P. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008; 46: 119-130.
12. Maia J, Vaz-da-Silva M, Almeida L, Falcão A, Silveira P, Guimarães S, Graziela P, Soares-da-Silva P. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R&D. 2005; 6: 201-206.
13. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995; 35: 1094-1102.
14. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30: 359-371.
15. Steinijans VW, Sauter R, Hauschke D. Reference tables for the intra-subject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther. 1995; 33: 427-430.
16. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005; 44: 721-729.
17. Yuen HY, Peh KK, Tan BL. Relation in vitro/in vivo data of two controlled-release metformin formulations. Drug Dev Ind Pharm. 1999; 25: 613-618.